Recursion Pharmaceuticals hopes to use AI to accelerate drug discovery in the healthcare industry. its ambitious plans are still unproven, and the business has no approved products of its own. Nvidia ...
Recursion Pharmaceuticals reported higher revenue than analysts expected for Q1 2024. The company has made significant advancements in its clinical pipeline, with multiple Phase 2 trials expected to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback